Newsletters

Catch Up On Past Newsletters

The Lobular Breast Cancer Alliance (LBCA) newsletter brings the latest information about invasive lobular carcinoma (ILC) and the organization to your inbox. If you missed a past issue or want to reread an interesting article, click on a link below catch up.

For more information about lobular breast cancer or to make a gift click here.  You can also click below to subscribe to our newsletter today!

2022

12/15/22 – ILC Research and LBCA at San Antonio Breast Cancer Symposium, Results of our Goal Performance Survey
11/22/22 – Announcing 2023 AACR/LBCA ILC Research Fellowship, A Message from our Scientific Advisiors, ILC Research at SABCS
11/17/22 – LBCA October Recap, The Doctor Is in and Discussing ILC, Dr. Rinath Jeselsohn Discusses her New ILC Research
10/05/22 – LBCA Is Raising Awareness that Breast Cancer Has Subtypes, New Imaging Research Grant, Advocate Chat with NCI
9/20/22 – Founder Leigh Pate’s Tribute Page, 2022 ILC Symposium Recap Recording, Dr. Christos Sotiriou’s Latest ILC Research 
8/25/22 – Register for ILC Symposium Recap, Meet New LBCA Chair, Dr. Matt Sikora Discusses Basic Research
7/21/22 – Remembering LBCA Founder Leigh Pate, 2022 ILC Symposium Recap, Dr. Rita Mukhtar’s Latest ILC Research
6/14/22 – Take LBCA’s Metastatic ILC Survey, Watch Our Cancer Moonshot Video, Learn About ILC from Volunteer Leaders
5/26/22 – Meet Our Newly Funded Researcher Karen Van Baelen, MD, Inaugural Volunteer Focus, Conversation with Dr. Chris Li
4/21/22 – Volunteer Message from our COO/Volunteer Coordinator, Metastatic ILC Webinar, New Advocate Registry
3/24/22 – New Partnerships with NBCC and COST, Amplifying Black Voices Across Cancer, Meet Dr. Jason Mouabbi
2/24/22 – LBCA Movie Focuse on ILC Issues, Remembering Meg Kotler, Meet Research Grantee Dr. Candace Frerich
1/20/22 – LBCA’s First Board of Directors, LPGA’s Angela Stanford Teams up with LBCA,  Guest Blog with Dr. Raquel Nunes
Scroll to Top

Join Us

Subscribe for the Latest News & Updates​

  • This field is for validation purposes and should be left unchanged.